Drug Trial Radar · NCT05729568
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
83
Actual
Start
May 15, 2023
Primary completion
Jul 2, 2024
Study completion Dec 2030
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Feb 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection. The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN, TAB and ZAB, versus continuing on baseline oral antiretroviral therapy (ART) as determined by the proportion of participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) ≥ 50 copies/mL at Week 26.
Conditions
- HIV-1 Infection
Interventions
TeropavimabDrug
Administered intravenously
ZinlirvimabDrug
Administered intravenously
Lenacapavir TabletDrug
Administered orally
Lenacapavir InjectionDrug
Administered subcutaneously
Antiretroviral TherapyDrug
Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot AlgorithmTime frame: Week 26
Locations
34 sites in 4 countries. Site status is shown where the registry gives one.
Ruane Clinical Research Group, Inc.
Los Angeles, California
Mills Clinical Research
Los Angeles, California
UC San Diego (UCSD) AntiViral Research Center (AVRC)
San Diego, California
Optimus Medical Group
San Francisco, California
University of Colorado Clinical and Translational Research Center
Aurora, Colorado
Yale University; School of Medicine; AIDS Program
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Midland Florida Clinical Research Center, LLC
DeLand, Florida
Can Community Health Care
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
Orlando Immunology Center
Orlando, Florida
Triple O Research Institute, P.A.
West Palm Beach, Florida
Emory University Hospital Midtown Infectious Disease Clinic
Atlanta, Georgia
Infectious Disease Specialists of Atlanta
Decatur, Georgia
Southhampton Healthcare, Inc
St Louis, Missouri
AXCES Research Group, LLC
Albuquerque, New Mexico
Montefiore Medical Center
The Bronx, New York
NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Duke University Health Center
Durham, North Carolina
Regional Center for Infectious Disease Research
Greensboro, North Carolina
The Brody School of Medicine at East Carolina University
Greenville, North Carolina
Rosedale Health and Wellness
Huntersville, North Carolina
Prisma Health - Clinical Research Unit
Columbia, South Carolina
St Jude Children's Research Hospital
Memphis, Tennessee
Central Texas Clinical Research
Austin, Texas
AIDS Arms, Inc. DBA Prism Health North Texas
Dallas, Texas
AXCES Research Group, LLC
El Paso, Texas
The Crofoot Research Center, INC
Houston, Texas
Clinical Alliance for Research & Education, Infectious Diseases LLC (CARE-ID)
Annandale, Virginia
East Sydney Doctors
Darlinghurst, New South Wales, Australia
Holdsworth House Medical Practice
Sydney, New South Wales, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Maple Leaf Research/Maple Leaf Medical Clinic
Toronto, Canada
Clinical Research Puerto Rico
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.